Advertisement
Advertisement
NUVL
Nuvalent, Inc. Class A Common Stock
102.12
USDSponsored
+0.88
+0.87%
May 22, 16:00 UTC -4
Closed
Pre-Market
102.72
+0.60
+0.59%
NUVL Earnings Reports
Positive Surprise Ratio
NUVL beat 8 of 20 last estimates.
40%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$1.43
Implied change from Q1 26 (Revenue/ EPS)
--
/+2.88%
Implied change from Q2 25 (Revenue/ EPS)
--
/+2.88%
Nuvalent, Inc. Class A Common Stock earnings per share and revenue
On May 07, 2026, NUVL reported earnings of -1.39 USD per share (EPS) for Q1 26, missing the estimate of -1.34 USD, resulting in a -3.41% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.78% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -1.43 USD, with revenue projected to reach -- USD, implying an increase of 2.88% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Nuvalent, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Nuvalent, Inc. Class A Common Stock reported EPS of -$1.39, missing estimates by -3.41%, and revenue of $0.00, 0% as expectations.
How did the market react to Nuvalent, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -1.78%, changed from $104.26 before the earnings release to $102.40 the day after.
When is Nuvalent, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Nuvalent, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Nuvalent, Inc. Class A Common Stock is expected to report EPS of -$1.43 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement